Glimifix M 2 mg/500 mg Tablet is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta-cell insulin secretion, thereby enhancing endogenous insulin levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or on monotherapy with either agent. Glimifix M should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea, vomiting, and diarrhea. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Regular monitoring of blood glucose, renal function, and hepatic parameters is recommended during therapy. Dose adjustments may be necessary based on therapeutic response and tolerability. Patients should be advised on lifestyle modifications including diet and exercise to optimize treatment outcomes. Glimifix M offers a synergistic approach to glycemic management, improving both fasting and postprandial blood glucose levels, thereby reducing the risk of diabetes-related complications.